Gilead Sciences, Inc.
333 Lakeside Drive
About Gilead Sciences, Inc.
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
1853 articles with Gilead Sciences, Inc.
U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the U.S. Food and Drug Administration (FDA) has approved an expansion of the pediatric indication of Epclusa® (sofosbuvir/velpatasvir) for the treatment of chronic hepatitis C virus (HCV) to now include children as young as 3 years of age, regardless of HCV genotype or liver disease severity
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC)
Satcher Health Leadership Institute At Morehouse School Of Medicine, With Support From Google.org And Gilead Sciences, Launches Health Equity Tracker To Study Racial Health Inequities Related To Covid-19
The Satcher Health Leadership Institute at Morehouse School of Medicine, with support from Gilead Sciences, Inc., Google.org, the Annie E. Casey Foundation, and the CDC Foundation announced the launch of the Health Equity Tracker, a comprehensive data platform that can highlight and address the impact of COVID-19 and other diseases on the Black, Indigenous, Latinx, Asian, Pacific Islander, and other vulnerable and marginalized communities.
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
NGM Bio's aldafermin failed to hit its primary endpoint in its Phase IIB trial because of that, the company decides to shift resources to other programs.
Gilead Sciences, Inc. and Kite, a Gilead Company, announced that 16 abstracts representing the breadth of the Gilead-Kite Oncology portfolio will be presented at the American Society of Clinical Oncology Annual Meeting from June 4-8, 2021.
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences
5/11/2021Despite the COVID-19 pandemic taking a hit on other industries, the biotech industry continues to grow and so do salaries. Biotech companies keep adding jobs and the market is hot! Check out these hot companies who are looking for candidates like you right now!
Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conferences:.
BioSpace takes an in-depth look at the Top 25 of Q1.
Gilead Sciences, Inc. announced that the company’s Board of Directors has declared a cash dividend of $0.71 per share of common stock for the second quarter of 2021.
“We have made strong progress in this first quarter, with our new partnership with Merck in long-acting HIV therapies, two newly approved indications in the U.S. for Trodelvy in metastatic triple-negative breast cancer and metastatic urothelial cancer, and the addition of Hepcludex to our portfolio,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that in response to the rapid increase in COVID-19 cases in India, the company is providing its voluntary licensing partners with technical assistance, support for the addition of new local manufacturing facilities and the donation of active pharmaceutical ingredient (API) to rapidly scale up production of remdesivir
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and Astra...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2021 financial results will be released on Thursday, April 29, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s first quarter 2021 financial results and will provide a business update.
The approval marks the second approval for Trodelvy, which Gilead gained through its $21 billion acquisition of Immunomedics.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Trodelvy® (sacituzumab govitecan-hziy) for use in adult patients with locally advanced or metastatic urothelial cancer (UC) who have previously received a platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor.
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the U.S. Food and Drug Administration (FDA) has granted full approval of Trodelvy
The agency granted full approval to Gilead Sciences’ Trodelvy (Sacituzumab govitecan-hziy) for adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more previous system therapies, at least one for metastatic disease.
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease